Cargando…

New atypical antipsychotics for schizophrenia: iloperidone

The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin type 2A (D(2)/5-HT(2A)) antagonist structur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caccia, Silvio, Pasina, Luca, Nobili, Alessandro
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846148/ https://www.ncbi.nlm.nih.gov/pubmed/20368905

Ejemplares similares

A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2013)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
por: Tonin, Fernanda S, et al.
Publicado: (2016)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study
por: Weiden, Peter J., et al.
Publicado: (2016)

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

Ventricular premature contractions associated with iloperidone
por: Achalia, Rashmin, et al.
Publicado: (2013)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka, Michal, et al.
Publicado: (2015)

Long-term efficacy and safety of iloperidone: an update
por: Rado, Jeffrey T, et al.
Publicado: (2014)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms
por: Danek, Przemysław J., et al.
Publicado: (2021)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Iloperidone-induced Galactorrhea in a Middle-aged Female
por: Dutta, Arghya, et al.
Publicado: (2012)

Iloperidone-induced ejaculatory dysfunction: A case series
por: Ravani, Niraj Narendra, et al.
Publicado: (2016)

Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia
por: Thériault, Rachel-Karson, et al.
Publicado: (2021)

The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions
por: Danek, Przemysław J., et al.
Publicado: (2020)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
por: Brasso, Claudio, et al.
Publicado: (2023)

Severity in schizophrenia patients receiving atypical antipsychotic medications
por: Alam Fatmi1j, Syed Meraj, et al.
Publicado: (2022)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Adherence and Persistence to Medical Therapy in Glaucoma: An Overview
por: Quaranta, Luciano, et al.
Publicado: (2023)

A case of iloperidone overdose in a 27-year-old man with cocaine abuse
por: Amon, Jin, et al.
Publicado: (2016)

Synthesis and Characterization of Carbon-11 Labeled Iloperidone for Imaging of α(1)-Adrenoceptor in Brain
por: Xu, Yulong, et al.
Publicado: (2020)

Peripheral Amino Acid Levels in Schizophrenia and Antipsychotic Treatment
por: De Luca, Vincenzo, et al.
Publicado: (2008)

Factors Associated with a High-Risk Profile for Developing Pressure Injuries in Long-Term Residents of Nursing Homes
por: Elli, Chiara, et al.
Publicado: (2022)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
por: Fujimaki, Koichiro, et al.
Publicado: (2012)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
por: Gilca, Marilena, et al.
Publicado: (2014)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

Anti-stress Properties of Atypical Antipsychotics
por: Sanson, Alice, et al.
Publicado: (2020)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs
por: Kucharska-Pietura, Katarzyna, et al.
Publicado: (2012)

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics
por: McEvoy, Joseph, et al.
Publicado: (2013)

Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia
por: Shrivastava, Amresh, et al.
Publicado: (2012)

Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
por: Kang, Shi Hyun, et al.
Publicado: (2015)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
por: Chen, Yi-Lung, et al.
Publicado: (2018)

Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
por: Behrouzian, Forouzan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_65eug3rfn9i100r29erqd3icua